Showing results (91-100 of 102) with videos related to

Sort By:
Pageof 11
Pharmaceutics|May 25, 2024
Impact of LS Mutation on Pharmacokinetics of Preventive HIV Broadly Neutralizing Monoclonal Antibodies: A Cross-Protocol Analysis of 16 Clinical Trials in People without HIVBryan T Mayer, Lily Zhang, Allan C deCamp, et al.
Journal of the International AIDS Society|June 4, 2025
Analytical treatment interruption among women with HIV in southern Africa who received VRC01 or placebo in the Antibody Mediated Prevention Study: ATI stakeholder engagement, implementation and early clinical dataShelly Karuna, Fatima Laher, Sufia Dadabhai, et al.
Science Translational Medicine|July 5, 2023
Broadly neutralizing antibody treatment maintained HIV suppression in children with favorable reservoir characteristics in BotswanaRoger L Shapiro, Gbolahan Ajibola, Kenneth Maswabi, et al.
Nature Communications|March 10, 2022
First-in-human immunoPET imaging of HIV-1 infection using <sup>89</sup>Zr-labeled VRC01 broadly neutralizing antibodyDenis R Beckford-Vera, Robert R Flavell, Youngho Seo, et al.
Medrxiv : the Preprint Server for Health Sciences|January 23, 2024
A Randomised Clinical Trial of the Safety and Pharmacokinetics of VRC07-523LS Administered via Different Routes and Doses (HVTN 127/HPTN 087)Stephen R Walsh, Cynthia L Gay, Shelly T Karuna, et al.
The Lancet. HIV|December 12, 2024
Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trialSrilatha Edupuganti, Christopher B Hurt, Kathryn E Stephenson, et al.
Nature Communications|August 28, 2024
Administration of anti-HIV-1 broadly neutralizing monoclonal antibodies with increased affinity to Fcγ receptors during acute SHIV<sub>AD8-EO</sub> infectionJoana Dias, Giulia Fabozzi, Slim Fourati, et al.
BMC Immunology|February 18, 2025
Pharmacokinetic interaction assessment of an HIV broadly neutralizing monoclonal antibody VRC07-523LS: a cross-protocol analysis of three phase 1 trials in people without HIVTariro D Chawana, Stephen R Walsh, Lynda Stranix-Chibanda, et al.
Science Translational Medicine|May 6, 2026
VRC01 with antiretroviral initiation in infants is well tolerated, and higher concentrations associate with greater HIV-1 DNA declinesAlka Khaitan, Jane C Lindsey, Edmund V Capparelli, et al.
Plos Medicine|June 24, 2024
Safety and pharmacokinetics of VRC07-523LS administered via different routes and doses (HVTN 127/HPTN 087): A Phase I randomized clinical trialStephen R Walsh, Cynthia L Gay, Shelly T Karuna, et al.
Pageof 11